Biocartis Group NV provided financial guidance for the fiscal year 2023. Building on the strong performance of 2022, the company expects to take a next significant step towards operating profitability, with: product related revenues of between EUR 55 million and EUR 60 million, reflecting growth of 25%-35% when excluding sales of SARS-CoV-2 tests that are expected to further decrease.